The “Healthcare” practice at MarketsandMarkets is pleased to announce its “Analyst Briefing Presentation” on the “Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market – Global Trends & Forecast to 2017”
The global radiopharmaceuticals market was valued at $3.8 billion in 2012 and is poised to reach $5.5 billion by 2017 at a CAGR of 7.8%.
The usage of radioisotopes is categorized into diagnostic and therapeutic applications. The global SPECT market accounted for a major share of the diagnostic segment in 2012. Significant radioisotopes in the diagnostic market are Tc-99m, Tl- 201, Ga-67, I0123, F-18, and Rb-82; the therapy market is dominated by I-131, Sm-153, Re-186, Y-90, and Lu-177.
The nuclear medicine market is driven by the increasing incidence of cancer and cardiac disorders, followed by the increasing use of SPECT and PET imaging procedures.This market is experiencing stringent regulations on production, usage, and transportation of these radiopharmaceuticals in the global market.
North America accounted for the largest market share of the global nuclear medicine market, followed by Europe in 2012. Other regions such as Asia and Rest of the world are promising markets. Considering investments and various initiatives, markets like China, The Netherlands, Australia, and Japan have been found to be significant.
The dominant players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Covidien, Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Siemens Healthcare (PETNET) (Germany).
The stable isotopes market was less than $150 million in 2012 and poised to grow at double-digit CAGR in the next 5 years. The market was led by two players – Cambridge Isotope Laboratories (CIL) and Sigma Aldrich – in 2012; they jointly contributed more than 90% to the global revenue.
The agenda for the briefing includes discussion on key high growth markets. Furthermore, a briefing will be conducted on the competitive scenario, geographical trends and opportunities with focus on geographies such as North America, Europe, Asia, and Rest of the world.
|Global Radiopharmaceutical & Enriched Stable Isotope Market|
|Global Radiopharmaceutical Market||A bottom-up approach was used to calculate the global market size, using Tc-99m & F-18 market numbers as the base|
|Global Diagnostic Radiopharmaceutical & Beta Emitter Market||A top-down approach was used to calculate the market for individual isotopes|
|Global Brachytherapy Market||A top-down approach was used to calculate the market for individual isotopes|
|Global Radiopharmaceutical Application Market||The market size is based on usage patterns, penetration rates, diagnostic procedures, and cost of isotopes; a top-down approach was applied|
|Global Enriched Stable Isotope Market||A top-down approach was used to calculate the market for individual isotopes|
|Global Enriched Stable Isotope Application Market||A top-down approach was used to calculate the total isotopes market|
All numbers obtained from either of the approaches were triangulated and validated through expert interviews.
|Radiopharmaceutical Market||Segmental revenue for individual companies were considered for the base year and divided by the total market size|
|Enriched Stable Isotope Market||Market share has been discussed on the basis of secondary data, available through paid and unpaid sources, analyzing product portfolios of major companies, and rating them on the basis of performance and quality. These data points were further validated by primary sources.|
Key Data Points from secondary sources
|Market Revenue||Company financials, magazines, journals, press releases, paid databases, and MnM data repository|
|Market Revenue of Companies||Annual reports, company websites, public databases, and MnM data repository|
(Market Dynamics, Market Trends)
|Annual reports, company websites, press releases, and MnM data repository|
|New Radiopharmaceuticals Market||Market share is low in developing and emerging countries in the base year 2012 due to conventional practices and limited reach of new isotopes in these regions|
|Pipeline drugs||Only drugs in late Phase 3 or those that have cleared Phase 3 clinical trials have been considered|
|Enriched Stable Isotope Market|
|North America||Government funding on research will not drastically change till 2017|
|Application Market||Percentage share for each application to be similar in all geographic regions in the base year 2012|
North – Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252